Background
Streptococcus pneumoniae (
S. pneumoniae) infections are the leading cause of death from a vaccine-preventable illness in children aged less than 5 years, accounting for 18.3% of severe pneumonia and 33% of death caused by pneumonia [
1].
S. pneumoniae can also cause invasive pneumococcal disease (IPD), including pneumonia, meningitis, osteomyelitis, and sepsis [
2]. IPD is defined as a disease in which
S. pneumoniae is cultured from normal sterile sites, such as blood, cerebrospinal fluid, pleural effusion, biopsy, joint effusion, or peritoneal effusion [
3]. Previous reports found that pneumococcal conjugate vaccine (PCV) immunization could effectively prevent IPD [
2,
4,
5]. Therefore, vaccine immunization is an excellent strategy to reduce the incidence and mortality of IPD.
However, PCV immunization is not considered a routine vaccination by the government in many countries, especially China. Hence, the incidence and mortality are still high in these countries. Although Suzhou is one of the wealthiest cities in China, only 2–10% of patients were vaccinated during the study period. Many studies identified some features of in-hospital IPD in adults and children [
6‐
9], but the initial clinical characteristics for prognosis were not reported. The symptoms and signs of IPD are related to many factors such as host immunity,
S. pneumoniae virulence, and site of infection [
10]. Early recognition and prompt diagnosis remain the challenges. The present study was performed to analyze the clinical features and outcomes of children, so as to find a better strategy for reducing the incidence and mortality of IPD within 24 h of the onset in China.
Results
Demographics
The median age of 97 children with laboratory-confirmed IPD was 1.88 (0.78–3.64) years. The mortality rate was 17.5% (17/97); 91.8% (89/97) were aged less than 5 years, and 53.6% (52/97) were aged less than 2 years. The nonsurvival group (n = 17) comprised 100% (17/17) aged less than 5 years and 82.4% (14/17) aged less than 2 years. The median age of the patients in the nonsurvival group was 0.69 (0.49–1.55) years, significantly less than 2.39 (0.90–3.81) years in the survival group (n = 80) (P = 0.001). The median age of patients in the meningitis group (n = 46) was 0.99 (0.64–2.35) years, significantly less than 2.78 (1.09–3.52) years in the non-meningitis group (n = 51) (P = 0.031). The median age was 1.54 (0.76–3.44) years in the sepsis group (n = 86) and 1.36 (0.73–2.31) years in the non-sepsis group (n = 11) (P = 0.065).
Clinical manifestations
Among the 97 specimens, blood culture specimens accounted for 61 patients (61/97, 62.9%), cerebrospinal fluid culture specimens for 27 patients (27/97, 27.8%), and pleural effusion culture specimens for 9 patients (9/97, 9.3%). Further, 42 patients had sepsis alone, 35 had sepsis with meningitis, 9 had sepsis with severe pneumonia, 1 had sepsis with osteomyelitis, and 11 had meningitis alone.
The incidence rates of hyperpyrexia (temperature more than 40 °C), vomiting (greater than three times a day), anorexia (50% less than usual), lethargy, and poor perfusion of extremities among nonsurvivors compared with survivors were 41% vs 12, 70% vs 30, 94% vs 60, 94% vs 36, and 76% vs 12%, respectively, which were significantly higher in the nonsurvival group than in the survival group within 24 h of the onset of the disease (Table
1). Hemoglobin (Hb), platelet (Plt) count, white blood cell count, and neutropenia levels were 94.29 ± 25.74, 215.07 ± 158.07, 8.45 ± 8.42 and 6.10 ± 6.62 in the nonsurvival group, and 110.42 ± 19.23, 352.06 ± 164.66, 19.74 ± 22.67, and 66.67 ± 19.26 in the survival group. The nonsurvival group had significantly lower hemoglobin (Hb) level and Plt count compared with the survival group. However, the C-reactive protein level was not statistically different between the two groups (
P = 0.968) (Table
1).
Table 1
Comparison of clinical manifestations between non-survivors and survivors of children with IPD
Age(y) | 0.69 (0.49, 1.55) | 2.39 (0.90, 3.81) | 0.001 |
Male | 11 (64.7%) | 45 (56.2%) | 0.522 |
PRISMIII score | 21.04 ± 10.09 | 6.78 ± 12.32 | 0.000 |
Symptoms and signs |
Hyperpyrexia | 7 (41.2%) | 10 (12.5%) | 0.010* |
Vomiting | 12 (70.6%) | 24 (30.0%) | 0.002 |
Anorexia | 16 (94.1%) | 48 (60.0%) | 0.007 |
Lethargy | 16 (94.1%) | 29 (36.3%) | 0.000 |
Oliguria | 4 (23.5%) | 12 (15.0%) | 0.295* |
Poor perfusion of extremities | 13 (76.5%) | 10 (12.5%) | 0.000* |
Disease category | | | 0.000 |
Sepsis | 0 | 42 | |
Sepsis with meningitis | 17 | 18 | |
Meningitis alone | 0 | 11 | |
Sepsis with pneumonia | 0 | 9 | |
Source of pathogens | | | 0.083 |
Blood | 9 | 52 | |
Cerebrospinal fluid | 8 | 19 | |
Pleural effusion | 0 | 9 | |
Laboratory results |
Hb(g/L) | 94.29 ± 25.74 | 110.42 ±19.23 | 0.006 |
WBC(× 109 /L) | 8.45 ± 8.42 | 19.74 ± 22.67 | 0.071 |
N#(× 109 /L) | 6.10 ±6.62 | 66.67 ± 19.26 | 0.052 |
L#(× 109 /L) | 29.48 ± 17.17 | 24.91 ± 17.34 | 0.478 |
Plt(× 109 /L) | 215.07 ± 158.07 | 352.06 ± 164.66 | 0.005 |
CRP (mg/L) | 40.20 ± 66.69 | 47.42 ± 69.43 | 0.968 |
The multivariate regression analysis showed that hyperpyrexia, vomiting, lethargy, and poor perfusion of extremities were independent risk factors for the in-hospital mortality of children with IPD (Table
2). The pediatric risk of mortality III (PRISM III) score was significantly higher in the nonsurvival group than in the survival group (Table
2). Shock, respiratory failure, AKI, and convulsions or coma in the early stage were rare, and therefore statistical analysis was not done. Two patients died and two were alive with shock, three patients died and one was alive with respiratory failure, and two patients died and one was alive with seizure. Only one patient showed AKI in the nonsurvival group.
Table 2
Multiple logistic regression analyses of early clinical manifestations potentially associated with in-hospital mortality
Age(y) | 1.649 (0.439, 1.187) | 0.199a |
PRISMIII score | 7.591 (1.028, 1.179) | 0.006b |
Hyperpyrexia | 5.372 (1.294, 21.710) | 0.020c |
Vomiting | 6.013 (1.023, 26.522) | 0.014c |
Lethargy | 9.633 (3.166, 164.297) | 0.002c |
Poor perfusion of extremities | 8.348 (1.910, 36.485) | 0.001c |
Selection of antibiotics
The frequency of antibiotic use was as follows: azithromycin 30.2% (19/63), cefazolin 17.5% (11/63), oxycephalosporin 15.9% (10/63), ceftriaxone 12.7% (8/63), cefonicid 11.1% (7/63), cefodizime 9.5% (6/63), ceftizoxime 9.5% (6/63), cefoxitin 7.9% (5/63), and cefuroxime 6.3% (4/63). The consistency between the choice of antibiotics and the drug sensitivity test was 22.7% (22/97). The rationality of antibiotic choice was 5.9% in the nonsurvival group, which was lower than 26.3% in the survival group (
P = 0.050) (Table
3). Besides, a comparison of the percentage of antibiotic change in survivors and nonsurvivors showed a high frequency of antibiotic replacement (88% vs 94%,
P = 0.261). The outcome was not related to the use of antibiotics orally or intravenously. The resistance rate in 97 cases of S. pneumoniae was 100% (97/97) to erythromycin, 97.9% (95/97) to clindamycin, 87.6% (85/97) to tetracycline, 72.2% (70/97) to sulfamethoxazole, 49.5% (48/97) to penicillin, 33.0% (32/97) to cefotaxime, 8.2% (8/97) to amoxicillin, 5.2% (5/97) to chloramphenicol, 0.0% (0/80) to vancomycin, and 0.0% (0/80) to levofloxacin.
Table 3
Comparison of rationality of antibiotic choice between non-survivors and survivors of children with IPD
whether used antibiotics | 12/17 (70.6%) | 52/80 (65.0%) | 0.288 |
whether used antibiotics intravenously | 10/14 (71.4%) | 45/80 (56.3%) | 0.840* |
whether the choice of antibiotics is consistent with drug susceptibility | 1/17 (5.9%) | 21/80 (26.3%) | 0.050* |
percentage of antibiotic change | 15/17 (88.2%) | 75/80 (93.8%) | 0.261 |
Serotype analysis
Ten serotypes of S. pneumoniae
were detected in 97 hospitalized children with laboratory-confirmed IPD, followed by 6B (24.7%, 24/97), 14 (20.6%, 20/97), 19F (18.6%, 18/97), 19A (15.5%, 15/97), 23F (7.2%, 7/97), 9 V (5.2%, 5/97), 20 (4.1%, 4/97), 15B/C (2.1%, 2/97), 6A (1.0%, 1/97), and 4 (1.0%, 1/97). However, six serotypes including 6B (35.3%, 6/17), 14 (23.5%, 4/17), 19F (23.5%, 4/17), 19A (5.9%, 1/17), 23F (5.9%, 1/17), and 20 (5.9%, 1/17) in nonsurvivors. No significant correlation was found between serotypes and vomiting, anorexia, drowsiness and shock, respiratory failure, AKI, convulsion, and coma. Moreover, no significant correlation was observed between serotypes and mortality and PRISMIII score.
Further, none of the 97 children with laboratory-confirmed IPD received a pneumococcal vaccine. The 7-valent PCV (PCV7) covered 77.3% (75/97) of the IPD serotype, which was significantly lower than 93.8% (91/97) of the 13-valent PCV (PCV13). The 7-valent
S. pneumoniae
vaccine (PCV7) covered 88.2% (15/17) of nonsurvivors, while 13-valent
S. pneumoniae
vaccine (PCV13) covered 94.1% (16/17) (Table
4).
Table 4
Serotype distribution analysis between the two groups
PCV7 serptypes | | | 75 |
6B | 6 | 18 | 24 |
14 | 4 | 16 | 20 |
19F | 4 | 14 | 18 |
23F | 1 | 6 | 7 |
4 | 0 | 1 | 1 |
9 V | 0 | 5 | 5 |
PCV13 serotypes not included in PCV7 | | | 16 |
6A | 0 | 1 | 1 |
19A | 1 | 14 | 15 |
3 | 0 | 0 | 0 |
Others | | | 6 |
20 | 1 | 3 | 4 |
15B/C | 0 | 2 | 2 |
Discussion
In this study, the median age of hospitalized children with laboratory-confirmed IPD was only 1.88 (0.78–3.64) years, accounting for 53.6% aged less than 2 years. The median age of 17 nonsurvivors was only 0.69 years, accounting for 82.4% aged less than 2 years. According to the reports on high-income countries, the annual incidence of IPD in children aged less than 2 years was 160/100,000 [
16], indicating that these children were at high risk of
S. pneumoniae infection. Additional studies showed
S. pneumoniae infection in infants from Papua New Guinea and Australia [
17,
18]. Moreover, approximately half of children from Sweden and the United States were infected with
S. pneumoniae at least once before the age of 2 years [
19,
20]; these results were the same as the present findings. The predisposing factors of this population were not fully understood. It was speculated that the infection might be related to the immature immune system of infants and young children [
21]. Therefore, it is recommended internationally to inoculate a four-time vaccination strategy of the PCV13 for individuals aged 2, 4, 6, and 12–15 months, and before the age of 2 years [
5].
Furthermore, children who died of IPD showed more nonspecific symptoms, such as recurrent hyperpyrexia, vomiting, lethargy, and poor perfusion of extremities in the early stage. Some vigilance and close observation of children with nonspecific symptoms in the early stage are required to deal with the progression of the disease. This study found that 43.7% (45/97) patients had a change in consciousness during admission, which was higher than that in 11.5% of other patients with pneumonia [
22]. All of the nonsurvivors were diagnosed with sepsis with meningitis, and therefore these signs might indicate increased intracranial pressure (IICP).
S. pneumoniae results not only in disruption of the blood–brain barrier but also in vascular and neuronal injury, finally leading to IICP [
22,
23]. Except for early antibiotic use, aggressive control of IICP is also important [
24]. Previous studies showed that corticosteroid treatment reduced the death rate of patients with meningitis and
S. pneumonia infection [
25]. Therefore, close monitoring of the child’s state is of great significance for the timely and effective treatment and prognosis of IPD.
The initial consistency rate between antibiotic selection and drug sensitivity was only 22.7%. The rationality of antibiotic choice in the survival group was 26.3%, which was about four times that in the nonsurvival group. It also suggested a trend toward the impact of a reasonable selection of early antibiotics on mortality. In the present study, the resistance rate of
S. pneumoniae was 100% to erythromycin, 49.5% to penicillin, 33.0% to cefotaxime, 8.2% to amoxicillin, and 0% to vancomycin or levofloxacin. The strains of nonsurvivors in this study were multi-drug resistant. Domestic and foreign reports also showed that
S. pneumoniae was generally multi-drug resistant, and the resistance to penicillin and cephalosporins increased [
6,
26,
27]. Compared with drug sensitivity analysis in the present study, a better consistency rate was achieved if the choice of antibiotics strictly abided by China’s “Guidelines for the Management of Community Communicable Pneumonia (2013 Revision)”. The results suggested that physicians should be encouraged to follow a standard protocol based on the local patterns of antimicrobial sensitivity for community-acquired infection with modifications in the hospital as needed following the documentation of antimicrobial resistance patterns [
28].
Ten serotypes of
S. pneumoniae were detected in 97 hospitalized children with laboratory-confirmed IPD and 6 serotypes in nonsurvivors; 6B was the leading serotype, followed by 14, 19F, 19A, and 23F, which were similar to the top 5 serotypes in the other cities in China, but the sequence was different. The serotypes of IPD cases in the multicenter study of Chinese hospitals were 19F, 14, 19A, 6B, and 23F [
29,
30]. In this study, the PCV13 could cover 93.8% of serotypes of IPD cases and 94.1% of nonsurvivors. A large number of studies also showed that PCV13 had a good coverage for the serotypes of IPD. The widespread vaccination of PCV13 in many countries has effectively reduced the incidence and mortality of IPD [
31,
32]. At present, China’s PCV13 has not been included in the first-line vaccination catalog. Moreover, this vaccine is expensive (800 RMB/dose, approximately 114 $/dose). Therefore, very few children receive the PCV13 vaccine. About 2–10% of patients were vaccinated during the study period in Suzhou. The high coverage rate of PCV13 indicated that PCV13 could prevent pneumococcal diseases effectively. Unfortunately, none of the children with IPD were vaccinated with PCV13 or PCV7 vaccine in this study. Therefore, PCV13 should be underscored as an agent for preventable mortality in young children (particularly those less than 2 years of age), and thus should be adopted as part of the routine immunization schedule in China.
The present study had several limitations. First, the data of illness onset and presentation to hospital between survivors and nonsurvivors were not specified. So, their influence on the results could not be ruled out. Second, this was a retrospective, single-center study, and the sample size was limited. These factors reduced the strength of the findings. In addition, due to false-negative culture results, some true IPD cases were not included. Next-generation sequencing might improve the diagnostic yield. More large-scale, comprehensive clinical studies and highly sensitive techniques are needed to confirm the conclusions.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.